Tirzepatide 40mg
Tirzepatide · 40mg vial
Research use only · Not for human or veterinary consumption · Not for self-administration
Tirzepatide is a 39-amino-acid peptide that activates both GIP and GLP-1 receptors. It is the active ingredient in specific prescription products; indications vary by product and country.
Pricing · per vial
Mix & match any vials — 2–4 −10%, 5+ −15%In transit · ETA 20 Nov
How it works
Dual incretin activity supports glucose-dependent insulin signalling and affects appetite and food intake. A fatty-acid side chain extends its action in approved formulations.
Research context
The FDA prescribing information for Mounjaro applies to its named, approved presentations. It should not be treated as interchangeable with an unbranded lyophilised vial.
Vial contents & handling
- 40mg tirzepatide
- Single lyophilised vial
Quality & sourcing. Sourced from established manufacturers who test using HPLC analysis. COA available on request — ask us on WhatsApp ↗
Storage: keep unopened lyophilised vials in a cool, dark place. Once reconstituted, store in the fridge at 2–8°C and use within 2 months.
Research reference dosage
40mg vial · 3ml water · 13.33mg/ml| Level | Amount | U100 units | Frequency |
|---|---|---|---|
| Beginner | 2.5mg | 18.75 units | Once weekly or split 2× weekly · any time |
| Intermediate | 5–7.5mg | 37.5–56.25 units | Once weekly or split 2× weekly · any time |
| Advanced | 10–15mg | 75–112.5 units | Once weekly or split 2× weekly · any time |
Fixed 3ml · U100 device (1 unit = 0.01ml). For split weekly schedules, use half the listed full-amount units per administration. Research reference only—not human-use guidance.